EP2068877A4 - Compounds and methods of modulating angiogenesis - Google Patents

Compounds and methods of modulating angiogenesis

Info

Publication number
EP2068877A4
EP2068877A4 EP07840438A EP07840438A EP2068877A4 EP 2068877 A4 EP2068877 A4 EP 2068877A4 EP 07840438 A EP07840438 A EP 07840438A EP 07840438 A EP07840438 A EP 07840438A EP 2068877 A4 EP2068877 A4 EP 2068877A4
Authority
EP
European Patent Office
Prior art keywords
compounds
methods
modulating angiogenesis
angiogenesis
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07840438A
Other languages
German (de)
French (fr)
Other versions
EP2068877A2 (en
Inventor
Tatiana Byzova
Ganapati Bhat
Weiy Feng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of EP2068877A2 publication Critical patent/EP2068877A2/en
Publication of EP2068877A4 publication Critical patent/EP2068877A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07840438A 2006-07-19 2007-07-19 Compounds and methods of modulating angiogenesis Withdrawn EP2068877A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83199206P 2006-07-19 2006-07-19
PCT/US2007/073877 WO2008011513A2 (en) 2006-07-19 2007-07-19 Compounds and methods of modulating angiogenesis

Publications (2)

Publication Number Publication Date
EP2068877A2 EP2068877A2 (en) 2009-06-17
EP2068877A4 true EP2068877A4 (en) 2011-09-21

Family

ID=38957616

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07840438A Withdrawn EP2068877A4 (en) 2006-07-19 2007-07-19 Compounds and methods of modulating angiogenesis

Country Status (2)

Country Link
EP (1) EP2068877A4 (en)
WO (1) WO2008011513A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ584330A (en) * 2007-10-04 2013-01-25 Bionomics Ltd Markers of endothelial cells and uses thereof
ES2575160T3 (en) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibitors of the interactions that bind the alpha subunit of beta integrin-protein G

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016241A1 (en) * 1996-10-15 1998-04-23 Vanderbilt University Method of disrupting cellular adhesion
WO1998022500A2 (en) * 1996-11-21 1998-05-28 Cor Therapeutics, Inc. Modulation of interactions between myosin and integrins
WO2001079144A2 (en) * 2000-04-14 2001-10-25 Cor Therapeutics, Inc. Fyn kinase as a target for modulation of integrin mediated signal transduction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
DK0973804T3 (en) 1997-04-07 2007-05-07 Genentech Inc Anti-VEGF antibodies
CA2410509A1 (en) * 2000-06-02 2001-12-13 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US6958340B2 (en) * 2001-08-01 2005-10-25 Merck & Co., Inc. Tyrosine kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016241A1 (en) * 1996-10-15 1998-04-23 Vanderbilt University Method of disrupting cellular adhesion
WO1998022500A2 (en) * 1996-11-21 1998-05-28 Cor Therapeutics, Inc. Modulation of interactions between myosin and integrins
WO2001079144A2 (en) * 2000-04-14 2001-10-25 Cor Therapeutics, Inc. Fyn kinase as a target for modulation of integrin mediated signal transduction

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRIEDLANDER MARTIN ET AL: "Involvement of integrins, alpha-v-beta-3 and alpha-v-beta-5 in ocular neovascular diseases", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, no. 18, 1996, pages 9764 - 9769, XP000986063, ISSN: 0027-8424 *
MAHABALESHWAR GANAPATI H ET AL: "Beta 3 integrin phosphorylation and VEGF signaling", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 106, no. 11, Part 1, 1 November 2005 (2005-11-01), pages 159A, XP009151001, ISSN: 0006-4971 *
See also references of WO2008011513A2 *
SOLDI RAFFAELLA ET AL: "Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 18, no. 4, 15 February 1999 (1999-02-15), pages 882 - 892, XP002656146, ISSN: 0261-4189 *

Also Published As

Publication number Publication date
WO2008011513A2 (en) 2008-01-24
EP2068877A2 (en) 2009-06-17
WO2008011513B1 (en) 2008-10-16
WO2008011513A3 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
HK1245088A1 (en) Modulation of activity of proneurotrophins
IL244442B (en) Substituted acylanilide compounds and uses thereof
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
GB0718972D0 (en) Compounds and methods of making the compounds
SI2040728T1 (en) Fkbp-l and uses thereof as inhibitors of angiogenesis
EP2023718A4 (en) Creatine-ligand compounds and methods of use thereof
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
GB2428544B (en) Configuration of remote devices
IL194028A0 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IL193271A0 (en) Modulation of bone formation
GB0705854D0 (en) Methods of construction
IL195992A0 (en) Transcription factor modulating compounds and methods of use thereof
IL196594A0 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
PL381862A1 (en) Application of pyridine compounds and the manner of treatment
EP1721158A4 (en) Modulators of angiogenesis
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
EP2068877A4 (en) Compounds and methods of modulating angiogenesis
TWI367210B (en) Estrogenic-active compounds and application thereof
IL194798A0 (en) Treatment of melanoma
EP2043428A4 (en) Modulators of rnf5 and uses thereof
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
GB0602857D0 (en) The treatment of sialorrhoea
TWM300229U (en) Improvement of lockset device
TWI347933B (en) Derivatives of binol and application thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090219

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110823

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/04 20060101AFI20110812BHEP

Ipc: A61P 35/00 20060101ALI20110812BHEP

Ipc: A61K 38/17 20060101ALI20110812BHEP

Ipc: A61K 31/47 20060101ALI20110812BHEP

Ipc: C07D 215/16 20060101ALI20110812BHEP

Ipc: A61K 38/08 20060101ALI20110812BHEP

Ipc: A61P 27/02 20060101ALI20110812BHEP

Ipc: C07D 215/20 20060101ALI20110812BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20171113

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180807

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20181218